Lupus nephritis

Minerva Medica

Volumn 98, Issue 6, 2007, Pages 749-758

  Sauter, M ^a   Anders, H J ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Lupus nephritis, diagnosis; Lupus nephritis, drug therpy; Lupus nephritis, physiopathology

Indexed keywords

ABETIMUS; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; B CELL ACTIVATING FACTOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IDEC 131; MYCOPHENOLIC ACID; PREDNISOLONE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIPLIZUMAB; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

B LYMPHOCYTE; CARDIOVASCULAR RISK; CELL INTERACTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; KIDNEY BIOPSY; LEUKOCYTURIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MICROSCOPY; NONHUMAN; PATHOGENESIS; PLASMAPHERESIS; PROGNOSIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REMISSION; REVIEW; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; URINALYSIS;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS;

EID: 38849138958     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (76)

1. Hochberg MC. Updating the American College of Rheumatology Revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
2. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al. The 1982 revised criteria for the classification of systemic lupus erythemathosus. Arthritis Rheum 1982;25:1271-7.
3. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1 000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993;72:113-24.
4. Kasitanon N, Magder LS, Petri M. Predictors of survival in systemic lupus erythematosus. Medicine (Baltimore) 2006;85:147-56.
5. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004;65:521-30.
6. Weening JJ, D'Agati BD, Schwartz MM et al., The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15:241-50.
7. Furness PN, Taub N. Interobserver reproducibility and application of the ISN/RPS classification of lupus nephritis-a UK-wide study. Am J Surg Pathol 2006;30:1030-5.
8. Tron F, Ganeval D, Droz D. Immunologically-mediated acute renal failure in nonglomerular origin in the course of systemic lupus erythematosus (SLE). Report of two cases. Am J Med 1979; 67: 529-32.
9. Singh AJ, Ucci A, Madias NE. Predominant tubulointerstitial nephritis. Am J Kidney Dis 1996;27:273-8.
10. Hahn BH. Antibodies to DNA. N Engl J Med 1998;338:1359-68.
11. Bootsma H, Spronk P, Derksen R, de Boer G, Wolters-Dicke H, Hermans J et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995;345:1595-9.
12. Rekvig OP, Kalaaji M, Nossent H. Anti-DNA antibody subpopulations and lupus nephritis. Autoimmun Rev 2004;3:1-6.
13. Chan TM, Chenk IK. Identification of endothelial cell membrane proteins that bind anti-DNA autoantibodies from patients with systemic lulus erythematosus by direct or indirect mechanisms. J Autoimmun 1997;10:433-9.
14. Chan TM, Leung JK, Ho SK, Yung S. Mesangial cell-binding anti-DNA antibodies in patients with systemic lupus erythematosus. J Am Soc Nephrol 2002;13:433-9.
15. Alarcon-Segovia D, Ruiz-Arguelles A, Llorente L. Broken dogma: penetration of autoantibodies into living cells: Immunol Today 1996;17:163-4.
16. Hsieh SC, Sun KH, Tsai CY, Tsai YY, Tsai ST, Huang DF et al. Monoclonal anti-double stranded DNA antibody is a leucocyte-binding protein to up-regulate inteleukin-8 gene expression and elicit apoptosis of normal human polymorhonuclear neutrophils. Rheumatology (Oxford) 2001;40:851-8.
17. Kubota T, Watanabe N, Kanai Y, Stollar BD. Enhancement of oxidative cleavage of DNA by the binding sites of two anit-double-stranded DNA antibodies. J Biol Chem 1996;271:6555-61.
18. Lai KN, Leung JC, Lai KB, Lai CK. Upregulation of adhesion molecule expression on endothelial cells by anti-DNA autoandibodies in systemic lupus erythematosus. Clin Immunol Immunopathol 1996;81:229-38.
19. Lai KN, Leung JC, Lai KB, Lai CK. Effect of anti-DNA autoantibodies on the gene expression of inteleukin 8, transforming growth factor-beta, and nitric oxide synthase in cultured endothelial cells. Scand J Rheumatol 1997;26:461-7.
20. Lai KN, Leung LC, Lai KB, Li PK, Lai CK. Anti-DNA autoantibodies stimulate the release of interleukin-1 and interleukin-6 from endothelial cells. J Pathol 1996;378:451-7.
21. Kamradt T, Mtchinson NA. Tolerance and autoimmunity. N Engl J Med 2001;344:655-64.
22. Walport MJ. Complement. Second of two parts. N Engl J Med 2001;344:1140-4.
23. Tang S, Sui SL, Lai KN. Pathogenesis of lupus nephritis: An update. Nephrology 2005:10,174-9.
24. Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. SLE, complement deficiency and apoptosis. Adv Immunol 2000,76:227-324.
25. Seelen MA, Trouw LA, Daha MR. Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. Curr Opin Nephrol Hypertens 2003;12:619-24.
26. Horvath L, Czirjak L, Fekete B, Jakab L, Pozsonyi T, Kalabay L et al. High levels of antibodies against C1q are associated with disease activity and nephritis but not with other organ manifestations in SLE patients. Clin Exp Rheumatol 2001;19:667-72.
27. Marto N, Bertolaccini ML, Calabuig E, Hughes GR, Khamashta MA. Anti-C1q antibodies in nephritis: correlation between titres and renal diseases activity and positive predictive value in systemic lupus erythematosu. Ann Rheum Dis 2005;64:444-8.
28. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001;166:6-10.
29. Patole PS, Grone HJ, Segerer S, Ciubar R, Belemezova E, Henger A et al. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J Am Soc Nephrol 2005;16:1326-38.
30. Anders HJ, Vielhauer V, Eis V, Linde Y, Kretzler M, Perez de Lema G et al. Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J 2004;18:534-6.
31. McCune WJ, Golbus J, Zeldes W, Bohlke P, Dunne R, Fox DA. Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus. N Engl J Med 1988;318:1423-31.
32. The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 2006;Arthritis Rheum 2006;54:421-32.
33. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000;35:904-14.
34. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406.
35. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, Danieli MG et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-31.
36. Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-9.
37. Hauser IA, Renders L, Radeke HH, Sterzel RB, Goppelt-Struebe M. Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol Dial Transplant 1999;14:58-63.
38. Badid C, Vincent M, McGregor B, Melin M, Hadj-Aissa A, Veysseyre C et al. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int 2000;58:51-61.
39. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343:1156-62.
40. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28.
41. Investor Update Roche.com [Internet]. Basel: Roche, c1996-1997 [cited 2007 June 06]. Available from: http://www.roche.com/inv-update-2007-06-27.
42. Fu LW, Yang LY, Chen WP, Lin CY. Clinical efficacy of cyclosporin a neoral in the treatment of paediatric lupus nephritis with heavy proteinuria. Br J Rheumatol 1998;37:217-21.
43. Favre H, Miescher PA, Huang YP, Chatelanat F, Mihatsch MJ. Ciclosporin in the treatment of lupus nephritis. Am J Nephrol 1989;9 Suppl 1:57-60.
44. Tam LS, Li EK, Leung CB, Wong KC, Lai FM, Wang A et al. Long-term treatment of lupus nephritis with cyclosporin A. QJM 1998;91:573-80.
45. Lewis EJ, Hunsicker LG, Lan SP, Rohde RD, Lachin JM. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med 1992;326:1373-9.
46. Braun N, Erley C, Klein R, Kotter I, Saal J, Risler T. Immunoadsorption onto protein A induces remission in severe systemic lupus erythematosus. Nephrol Dial Transplant 2000;15:1367-72.
47. Pfueller B, Wolbart K, Bruns A, Burmester GR, Hiepe F. Successful treatment of patients with systemic lupus erythematosus by immunoadsorption with a C1q column: a pilot study. Arthritis Rheum 2001;44:1962-3.
48. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O'Nan P et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80.
49. Chan TM, Li FK, Hao WK, Chan KW, Lui SL, Tang S et al. Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus 1999;8:545-51.
50. Mok CC, Ying KY, Lau CS, Yim CW, Ng WL, Wong WS et al. Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial. Am J Kidney Dis 2004;43:269-76.
51. Kapitsinou PP, Boletis JN, Skopouli FN, Boki KA, Moutsopoulos HM. Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology (Oxford) 2004;43:377-80.
52. Spetie DN, Tang Y, Rovin BH, Nadasdy T, Nadasdy G, Pesavento TE et al. Mycophenolate therapy of SLE membranous nephropathy. Kidney Int 2004;66:2411-5.
53. Karim MY, Pisoni CN, Ferro L, Tungekar MF, Abbs IC, D'Cruz DP et al. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology (Oxford) 2005;44:1317-21.
54. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002;46:2673-7.
55. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005;44:1542-5.
56. Ng KP, Leandro MJ, Edwards JC, Ehrenstein MR, Cambridge G, Isenberg DA. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis 2006;65:942-5.
57. Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005;52:501-13.
58. Abetimus: Abetimus sodium, LJP 394. BioDrugs 2003;17:212-5.
59. Alarcón-Segovia D, Tumlin JA, Furie RA, McKay JD, Cardiel MH, Strand V et al. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003;48:442-54.
60. Quezada SA, Eckert M, Adeyi OA, Schned AR, Noelle RJ, Burns CM. Distinct mechanisms of action of anti-CD 154 in early versus late treatment of murine lupus nephritis. Arthritis Rheum 2003;48:2541-54.
61. Boumpas DT, Furie R, Manzi S, Illei GG, Wallace DJ, Balow JE et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003;48:719-27
62. Kalunian KC, Davis JC, Merrill JT, Totoritis MC, Wofsy D; IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:3251-8.
63. Furie R, Stohl W, Ginzler E, et al. Safety, pharmacokinetic and pharmacodynamic results of a phase I single and double dose-escalation study of lymphoStat-B (human monoclonal antibody to BLyS) in SLE patients [abstract]. Arthritis Theum 2003;48:S377.
64. Wallace DJ, Lisse J, Stohl W, McKay J, Boling E, Merrill JT. Belimumab (BMAB), a fully human monoclonal antibody to B-lymphocyte stimulator (BLYS), show bioactivity and reduces systemic lupus erythematosus disease activity. Ann Rheum Dis 2006;65:62.
65. Boswell JM, Yui MA, Burt DW, Kelley VE. Increased tumor necrosis factor and IL-1 beta gene expression in the kidneys of mice with lupus nephritis. J Immunol 1988;141:3050-4.
66. Malide D, Russo P, Bendayan M. Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients. Hum Pathol 1995;26:558-64.
67. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996;35:1067-74.
68. Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004;50:3161-9.
69. Hayat SJ, Uppal SS, Narayanan Nampoory MR, Johny KV, Gupta R, Al-Oun M. Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis. Clin Rheumatol 2007;26:973-5.
70. Micheloud D, Nuno L, Rodriguez-Mahou M, Sanchez-Ramon S, Ortega MC, Aguaron A et al. Efficacy and safety of Etanercept, high-dose intravenous gamma-globulin and plasmapheresis combined therapy for lupus diffuse proliferative nephritis complicating pregnancy. Lupus 2006;15:881-5.
71. De Bandt M, Sibilia J, Le Loet X, Prouzeau S, Fautrel B, Marcelli C et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005;7:R545-51.
72. Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, Kaufman D et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005;20:1400-6.
73. Benucci M, Li Gobbi F, Fossi F, Manfredi M, Del Rosso A. Drug-induced lupus after treatment with infliximab in rheumatoid arthritis.J Clin Rheumatol 2005;11:47-9.
74. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005;34:819-36.
75. Ostendorf B, Iking-Konert C, Kurz K, Jung G, Sander O, Schneider M. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis 2005;64:630-3.
76. Davidson A, Aranow C. Pathogenesis and treatment of systemic lupus erythematosus nephritis. Curr Opin Rheumatol 2006;18:468-75.